Cardiomyocyte changes in the metabolic syndrome and implications for endogeneous protective strategies

References

• Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985;75(3):809-17
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37(12):1595-607
   PubMed Web of Science ®Google Scholar
• Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149(7):1514-20
   PubMedGoogle Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23(5):469-80
   PubMed Web of Science ®Google Scholar
• Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011;34(1):216-19
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356-9
   PubMed Web of Science ®Google Scholar
• Lee IM, Manson JE, Hennekens CH, Paffenbarger RS. Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA 1993;270(23):2823-8
   PubMed Web of Science ®Google Scholar
• El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004;15(11):2816-27
   PubMedGoogle Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112(12):1821-30
   PubMed Web of Science ®Google Scholar
• Belalcazar LM, Lang W, Haffner SM, et al. Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. J Lipid Res 2012;53(12):2726-33
   PubMed Web of Science ®Google Scholar
• Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987;16(2):235-51
   PubMed Web of Science ®Google Scholar
• Zoico E, Rossi A, Di Francesco V, et al. Adipose tissue infiltration in skeletal muscle of healthy elderly men: relationships with body composition, insulin resistance, and inflammation at the systemic and tissue level. J Gerontol A Biol Sci Med Sci 2010;65(3):295-9
   PubMed Web of Science ®Google Scholar
• Fuentes E, Fuentes F, Vilahur G, et al. Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm 2013;2013:136584
   PubMedGoogle Scholar
• Messerli FH, Ventura HO, Reisin E, et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982;66(1):55-60
   PubMedGoogle Scholar
• Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987;147(10):1725-8
   PubMedGoogle Scholar
• Aroor AR, McKarns S, Demarco VG, et al. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013;62(11):1543-52
   PubMed Web of Science ®Google Scholar
• Jones PP, Snitker S, Skinner JS, Ravussin E. Gender differences in muscle sympathetic nerve activity: effect of body fat distribution. Am J Physiol 1996;270(2 Pt 1):E363-6
   Google Scholar
• Abate NI, Mansour YH, Tuncel M, et al. Overweight and sympathetic overactivity in black Americans. Hypertension 2001;38(3):379-83
   PubMedGoogle Scholar
• Kassab S, Kato T, Wilkins FC, et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995;25(4 Pt 2):893-7
   PubMedGoogle Scholar
• Carlson SH, Shelton J, White CR, Wyss JM. Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats. Hypertension 2000;35(1 Pt 2):403-408
   PubMed Web of Science ®Google Scholar
• Collins S, Kuhn CM, Petro AE, et al. Role of leptin in fat regulation. Nature 1996;380(6576):677
   PubMed Web of Science ®Google Scholar
• Harada K, Shen WJ, Patel S, et al. Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice. Am J Physiol Endocrinol Metab 2003;285(6):E1182-95
   Google Scholar
• Haynes WG, Sivitz WI, Morgan DA, et al. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30(3 Pt 2):619-23
   PubMedGoogle Scholar
• Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997;80(9B):9J-14J
   Google Scholar
• Engeli S, Sharma AM. Role of adipose tissue for cardiovascular-renal regulation in health and disease. Horm Metab Res 2000;32(11-12):485-99
   PubMedGoogle Scholar
• Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003;52(4):942-7
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42(1):76-81
   PubMed Web of Science ®Google Scholar
• Lamounier-Zepter V, Look C, Alvarez J, et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 2009;105(4):326-34
   PubMed Web of Science ®Google Scholar
• Ishimura S, Furuhashi M, Watanabe Y, et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One 2013;8(11):e81318
   Google Scholar
• Neeland IJ, Gupta S, Ayers CR, et al. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging 2013;6(5):800-7
   PubMed Web of Science ®Google Scholar
• Hayden MR, Tyagi SC. Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit 2003;9(7):SR35-52
   PubMedGoogle Scholar
• Villarreal FJ, MacKenna DA, Omens JH, Dillmann WH. Myocardial remodeling in hypertensive Ren-2 transgenic rats. Hypertension 1995;25(1):98-104
   PubMedGoogle Scholar
• Kangas P, Tikkakoski AJ, Tahvanainen AM, et al. Metabolic syndrome may be associated with increased arterial stiffness even in the absence of hypertension: a study in 84 cases and 82 controls. Metabolism 2013;62(8):1114-22
   PubMed Web of Science ®Google Scholar
• McCarthy CG, Goulopoulou S, Wenceslau CF, et al. Toll-Like Receptors and Damage-Associated Molecular Patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol 2014;306(2):H184-96
   Google Scholar
• Hayden MR, Chowdhury N, Govindarajan G, et al. Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome. J Cardiometab Syndr 2006;1(5):326-33
   PubMedGoogle Scholar
• Hayden MR, Tyagi SC. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 2002;3(4):86-108
   PubMedGoogle Scholar
• Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003;2:2
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241(19):2035-8
   PubMed Web of Science ®Google Scholar
• Lastra G, Manrique CM, Hayden MR. The role of beta-cell dysfunction in the cardiometabolic syndrome. J Cardiometab Syndr 2006;1(1):41-6
   PubMedGoogle Scholar
• Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30(6):595-602
   PubMed Web of Science ®Google Scholar
• Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007;115(12):1544-50
   PubMed Web of Science ®Google Scholar
• Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68(1):85-9
   PubMed Web of Science ®Google Scholar
• Van den Bergh A, Flameng W, Herijgers P. Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail 2006;8(8):777-83
   PubMedGoogle Scholar
• Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008;52(22):1793-9
   PubMedGoogle Scholar
• Nelson MD, Victor RG, Szczepaniak EW, et al. Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am J Cardiol 2013;112(7):1019-24
   PubMedGoogle Scholar
• Mahmod M, Bull S, Suttie JJ, et al. Myocardial steatosis and left ventricular contractile dysfunction in patients with severe aortic stenosis. Circ Cardiovasc Imaging 2013;6(5):808-16
   PubMedGoogle Scholar
• Tyagi SC, Hayden MR. Role of nitric oxide in matrix remodeling in diabetes and heart failure. Heart Fail Rev 2003;8(1):23-8
   PubMedGoogle Scholar
• Hayden MR, Stump CS, Sowers JR. Introduction: organ involvement in the cardiometabolic syndrome. J Cardiometab Syndr 2006;1(1):16-24
   PubMedGoogle Scholar
• Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006;98(5):596-605
   PubMed Web of Science ®Google Scholar
• He L, Kim T, Long Q, et al. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 2012;126(14):1705-16
   PubMedGoogle Scholar
• Rosa CM, Xavier NP, Henrique Campos D, et al. Diabetes mellitus activates fetal gene program and intensifies cardiac remodeling and oxidative stress in aged spontaneously hypertensive rats. Cardiovasc Diabetol 2013;12(1):152
   PubMedGoogle Scholar
• Ames EG, Lawson MJ, Mackey AJ, Holmes JW. Sequencing of mRNA identifies re-expression of fetal splice variants in cardiac hypertrophy. J Mol Cell Cardiol 2013;62:99-107
   PubMedGoogle Scholar
• Dirkx E, da Costa Martins PA, De Windt LJ. Regulation of fetal gene expression in heart failure. Biochim Biophys Acta 2013;1832(12):2414-24
   PubMedGoogle Scholar
• Nevelsteen I, Bito V, Van der Mieren G, et al. ACE-inhibition, but not weight reduction restores cardiomyocyte response to β-adrenergic stimulation in the metabolic syndrome. BMC Cardiovasc Disord 2013;13(1):51
   PubMedGoogle Scholar
• Lebeche D, Davidoff AJ, Hajjar RJ. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008;5(11):715-24
   PubMedGoogle Scholar
• Van den Bergh A, Vanderper A, Vangheluwe P, et al. Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res 2008;77(2):371-9
   PubMedGoogle Scholar
• Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347(5):305-13
   PubMed Web of Science ®Google Scholar
• Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101(17):2118-21
   PubMed Web of Science ®Google Scholar
• Wookey PJ, Cao Z, Cooper ME. Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension. Miner Electrolyte Metab 1998;24(6):389-99
   PubMedGoogle Scholar
• Rocchini AP, Moorehead C, DeRemer S, et al. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension 1990;15(6 Pt 2):861-6
   PubMedGoogle Scholar
• Wong WT, Tian XY, Xu A, et al. Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid Redox Signal 2010;13(6):757-68
   PubMedGoogle Scholar
• Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997;432:35-44
   PubMed Web of Science ®Google Scholar
• Sciarretta S, Paneni F, Palano F, et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009;116(6):467-77
   PubMed Web of Science ®Google Scholar
• Corsetti G, Pasini E, Ferrari-Vivaldi M, et al. Metabolic syndrome and chronic simvastatin therapy enhanced human cardiomyocyte stress before and after ischemia-reperfusion in cardio-pulmonary bypass patients. Int J Immunopathol Pharmacol 2012;25(4):1063-74
   PubMedGoogle Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498-504
   PubMed Web of Science ®Google Scholar
• Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden. Eur Heart J 1997;18(5):754-61
   PubMedGoogle Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2):434-44
   PubMed Web of Science ®Google Scholar
• Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281(14):1291-7
   PubMed Web of Science ®Google Scholar
• Piper HM, Kasseckert S, Abdallah Y. The sarcoplasmic reticulum as the primary target of reperfusion protection. Cardiovasc Res 2006;70(2):170-3
   PubMedGoogle Scholar
• Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 2007;12(5):815-33
   PubMed Web of Science ®Google Scholar
• Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960;70:68-78
   PubMedGoogle Scholar
• Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985;76(5):1713-19
   PubMed Web of Science ®Google Scholar
• Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285(2):H579-88
   PubMed Web of Science ®Google Scholar
• Okamoto F, Allen BS, Buckberg GD, et al. Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg 1986;92(3 Pt 2):613-20
   PubMed Web of Science ®Google Scholar
• Peng CF, Murphy ML, Colwell K, Straub KD. Controlled versus hyperemic flow during reperfusion of jeopardized ischemic myocardium. Am Heart J 1989;117(3):515-22
   PubMedGoogle Scholar
• Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74(5):1124-36
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993;72(6):1293-9
   PubMedGoogle Scholar
• Yellon DM, Baxter GF. A “second window of protection” or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol 1995;27(4):1023-34
   PubMedGoogle Scholar
• Kaljusto ML, Mori T, Mohammad Husain Rizvi S, et al. Postconditioning in rats and mice. Scand Cardiovasc J 2006;40(6):334-41
   PubMedGoogle Scholar
• Bouhidel O, Pons S, Souktani R, et al. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol 2008;295(4):H1580-6
   Google Scholar
• Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004;95(3):230-2
   PubMed Web of Science ®Google Scholar
• Kin H, Zhao ZQ, Sun HY, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004;62(1):74-85
   PubMed Web of Science ®Google Scholar
• Argaud L, Gateau-Roesch O, Raisky O, et al. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005;111(2):194-7
   PubMed Web of Science ®Google Scholar
• Darling CE, Jiang R, Maynard M, et al. Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am J Physiol Heart Circ Physiol 2005;289(4):H1618-26
   Google Scholar
• Iliodromitis EK, Georgiadis M, Cohen MV, et al. Protection from postconditioning depends on the number of short ischemic insults in anesthetized pigs. Basic Res Cardiol 2006;101:6
   Google Scholar
• Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005;112(14):2143-8
   PubMed Web of Science ®Google Scholar
• Thibault H, Piot C, Ovize M. Postconditioning in man. Heart Fail Rev 2007;12(3-4):245-8
   PubMedGoogle Scholar
• Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter Cardiovasc Interv 2008;72(2):212-20
   PubMed Web of Science ®Google Scholar
• Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation 2008;117(8):1037-44
   PubMed Web of Science ®Google Scholar
• Zatta AJ, Kin H, Lee G, et al. Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling. Cardiovasc Res 2006;70(2):315-24
   PubMedGoogle Scholar
• Yang XM, Philipp S, Downey JM, Cohen MV. Postconditioning’s protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005;100(1):57-63
   PubMedGoogle Scholar
• Bopassa JC, Ferrera R, Gateau-Roesch O, et al. PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res 2006;69(1):178-85
   PubMedGoogle Scholar
• Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol 2006;290(1):H441-9
   Google Scholar
• Morrison RR, Tan XL, Ledent C, et al. Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol 2007;293(4):H2523-9
   Google Scholar
• Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 2008;103(3):203-15
   PubMedGoogle Scholar
• Kin H, Zatta AJ, Lofye MT, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005;67(1):124-33
   PubMedGoogle Scholar
• da Silva R, Grampp T, Pasch T, et al. Differential activation of mitogen-activated protein kinases in ischemic and anesthetic preconditioning. Anesthesiology 2004;100(1):59-69
   PubMedGoogle Scholar
• Sun HY, Wang NP, Halkos M, et al. Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Apoptosis 2006;11(9):1583-93
   PubMedGoogle Scholar
• Behrends M, Schulz R, Post H, et al. Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs. Am J Physiol Heart Circ Physiol 2000;279(3):H1111-19
   Google Scholar
• Argaud L, Gateau-Roesch O, Augeul L, et al. Increased mitochondrial calcium coexists with decreased reperfusion injury in postconditioned (but not preconditioned) hearts. Am J Physiol Heart Circ Physiol 2008;294(1):H386-91
   Google Scholar
• Schulz R, Boengler K, Totzeck A, et al. Connexin 43 in ischemic pre- and postconditioning. Heart Fail Rev 2007;12(3-4):261-6
   PubMed Web of Science ®Google Scholar
• Lucchinetti E, da Silva R, Pasch T, et al. Anaesthetic preconditioning but not postconditioning prevents early activation of the deleterious cardiac remodelling programme: evidence of opposing genomic responses in cardioprotection by pre- and postconditioning. Br J Anaesth 2005;95(2):140-52
   PubMedGoogle Scholar
• Van Der Mieren G, Flameng W, Herijgers P. [The effect of type II diabetes and the metabolic syndrome on cardiac second window preconditioning]. Verh K Acad Geneeskd Belg 2008;70(4):221-44
   PubMedGoogle Scholar
• Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007;59(4):418-58
   PubMed Web of Science ®Google Scholar
• Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 2012;11:67
   PubMed Web of Science ®Google Scholar
• Fullmer TM, Pei S, Zhu Y, et al. Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms. J Mol Cell Cardiol 2013;64:20-9
   PubMedGoogle Scholar
• Oosterlinck W, Dresselaers T, Geldhof V, et al. Diabetes mellitus and the metabolic syndrome do not abolish, but might reduce, the cardioprotective effect of ischemic postconditioning. J Thorac Cardiovasc Surg 2013;145(6):1595-602
   PubMedGoogle Scholar
• Tsang A, Hausenloy DJ, Mocanu MM, et al. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005;54(8):2360-4
   PubMedGoogle Scholar
• Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;29(9):2102-7
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Lindström J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2005;54(1):158-65
   PubMed Web of Science ®Google Scholar
• Gaede PH, Jepsen PV, Larsen JN, et al. [The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. Ugeskr Laeger 2003;165(26):2658-61
   PubMedGoogle Scholar
• Utz W, Engeli S, Haufe S, et al. Moderate dietary weight loss reduces myocardial steatosis in obese and overweight women. Int J Cardiol 2013;167(3):905-9
   PubMed Web of Science ®Google Scholar
• Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369(2):145-54
   PubMed Web of Science ®Google Scholar
• AlGhatrif M, Watts VL, Niu X, et al. Beneficial cardiac effects of caloric restriction are lost with age in a murine model of obesity. J Cardiovasc Transl Res 2013;6(3):436-45
   PubMedGoogle Scholar
• Iozzo P, Lautamaki R, Borra R, et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab 2009;94(11):4472-82
   PubMedGoogle Scholar
• Frigolet ME, Torres N, Tovar AR. The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem 2013;24(12):2003-15
   PubMedGoogle Scholar
• Deer RR, Heaps CL. Exercise training enhances multiple mechanisms of relaxation in coronary arteries from ischemic hearts. Am J Physiol Heart Circ Physiol 2013;305(9):H1321-31
   Google Scholar
• Van der Mieren G, Nevelsteen I, Vanderper A, et al. Angiotensin-converting enzyme inhibition and food restriction restore delayed preconditioning in diabetic mice. Cardiovasc Diabetol 2013;12:36
   PubMedGoogle Scholar
• Van der Mieren G, Nevelsteen I, Vanderper A, et al. Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury. Cardiovasc Diabetol 2012;11:89
   PubMedGoogle Scholar
• Hermida N, Markl A, Hamelet J, et al. HMG-CoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovasc Res 2013;99(1):44-54
   PubMedGoogle Scholar
• Moura LM, Ramos SF, Kristensen SD, et al. Rosuvastatin slows the development of diastolic dysfunction in calcific aortic stenosis. J Heart Valve Dis 2012;21(4):463-72
   PubMedGoogle Scholar
• Liao Y, Zhao H, Ogai A, et al. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 2008;31(2):335-44
   PubMedGoogle Scholar
• Zhao H, Liao Y, Minamino T, et al. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res 2008;31(10):1977-87
   PubMedGoogle Scholar
• Okada K, Minamino T, Tsukamoto Y, et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 2004;110(6):705-12
   PubMed Web of Science ®Google Scholar
• Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 2011;106(6):925-52
   PubMedGoogle Scholar
• Hausenloy DJ, Wynne AM, Mocanu MM, Yellon DM. Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. J Cardiovasc Pharmacol Ther 2013;18(3):263-9
   PubMed Web of Science ®Google Scholar
• Chinda K, Chattipakorn S, Chattipakorn N. Cardioprotective effects of incretin during ischaemia-reperfusion. Diab Vasc Dis Res 2012;9(4):256-69
   PubMed Web of Science ®Google Scholar
• Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011;25(1):13-20
   PubMedGoogle Scholar
• Fan Y, Yang S, Zhang X, et al. Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats. Clin Exp Pharmacol Physiol 2012;39(11):938-43
   PubMedGoogle Scholar
• Laflamme MA, Murry CE. Heart regeneration. Nature 2011;473(7347):326-35
   PubMed Web of Science ®Google Scholar
• Rota M, LeCapitaine N, Hosoda T, et al. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res 2006;99(1):42-52
   PubMed Web of Science ®Google Scholar
• Beltrami AP, Cesselli D, Beltrami CA. Stem cell senescence and regenerative paradigms. Clin Pharmacol Ther 2012;91(1):21-9
   PubMedGoogle Scholar